Delivery Order SPE2DR25D9222-SPE2DR26FHLB1
Award Date 3/23/26
Potential Completion Date 4/13/26
Potential Value $3.9K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a $3,923.82 delivery order to DMS Pharmaceutical Group Inc. on March 3, 2026, for Nuplazid 34 mg capsules under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The delivery order is issued under the PPV-G GEN V, a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 13, 2026, for $11,771.46 to supply Nuplazid 34 mg capsules under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the PPV-G GEN V, a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 12, 2026, for $11,771.46 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Nuplazid 34 mg capsules. DMS Pharmaceutical Group Inc. is a woman-owned small business. The parent contract, SPE2DR, is a single-award indefinite delivery contract with a $499.9 million ceiling and ultimate completion date of December 31, 2036, supporting pharmaceutical supply to...
- The Defense Logistics Agency issued a $11,771.46 delivery order to DMS Pharmaceutical Group Inc. on February 4, 2026, for Nuplazid 34 mg capsule 30-count units under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the PPV-G GEN V, a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 18, 2026, for Nuplazid 34 mg capsules, with a ceiling value of $3,923.82. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract that authorizes firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide. Place...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $11,771.46 for supply of Nuplazid 34 mg capsule 30-count units, with ultimate completion by March 3, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the company's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) Indefinite Delivery Contract (SPE2DR), a single-award DLA pharmaceutical supply...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for NUPLAZID 34 mg capsule 30s with a ceiling value of $3,923.82. The order was issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract that authorizes firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities...
- The Defense Logistics Agency awarded a delivery order valued at $3,923.82 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packages). The delivery order, issued on January 15, 2026, with an ultimate completion date of February 6, 2026, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a $21,177.78 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in quantities of 30. The delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group was...
- The Defense Logistics Agency awarded a $10,588.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS...
- SPE2DR25D9222Indefinite Delivery Contract
- SPE2DR25D9222-SPE2DR26FHLB1Delivery Order
The Defense Logistics Agency issued a $3,923.82 delivery order to DMS Pharmaceutical Group Inc. on March 23, 2026, for Nuplazid 34 mg capsules under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order is firm fixed price with an ultimate completion date of April 13, 2026. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA, which carries a $499.999 billion ceiling and runs through December 31, 2036.
Generated 6/21/26, 11:01 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 3/22/26 |